Form 4 for AKTS Aktis Oncology, Inc.
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-12 · accession 0001193125-26-010575 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-01-12 | 2026-01-12 | AKTS | Segal Lloyd Mitchell | Dir | C - Cnv Deriv | — | +19.6K | 19.6K | New | — |
| DMI | 2026-01-12 | 2026-01-12 | AKTS | Segal Lloyd Mitchell | Dir | C - Cnv Deriv | $0.00 | -74.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | C | A | 19,631 | — | 19,631 | I See Footnote | — | — | (F1) Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 3.8044-for-1 basis without payment of further consideration. (F2) Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. |
| 2 | Derivative | Series B Redeemable Convertible Preferred Stock | 2026-01-12 | C | D | 24,687 | $0.00 | 0 | I See Footnote | — · — to — | 6,489 Common Stock | (F2) Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. (F3) The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| 3 | Derivative | Series A Redeemable Convertible Preferred Stock | 2026-01-12 | C | D | 50,000 | $0.00 | 0 | I See Footnote | — · — to — | 13,142 Common Stock | (F2) Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc. (F3) The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |